Ignite Creation Date:
2024-05-05 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00355407
Status:
COMPLETED
Last Update Posted:
2009-03-13
First Post:
2006-07-19
Brief Title:
Darbepoetin Alfa Aranesp Following Allogeneic Stem Cell Transplantation
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
A Pilot Study of Darbepoetin Alfa Aranesp Following Allogeneic Stem Cell Transplantation
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out if Darbepoetin alfa is effective in treating low red blood cell levels after allogeneic stem cell transplant Darbepoetin alfa has been shown to help raise red blood cell levels without blood transfusions
Detailed Description:
Participants will receive Darbepoetin alfa through an injection under the skin about 28-35 days after their allogeneic stem cell transplant They will continue to receive the study drug once every three weeks for a maximum of four doses
Blood tests will be performed at weeks 3 6 9 and 12 The blood tests done at week three will check to make sure the participant has enough iron in their system If not they will need to take an iron supplement Participants will also take a folate supplement to help cell growth and reproduction
Blood tests will be performed at weeks 3 6 9 and 12 The blood tests done at week three will check to make sure the participant has enough iron in their system If not they will need to take an iron supplement Participants will also take a folate supplement to help cell growth and reproduction
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None